hydroxychloroquine has been researched along with Anti-Phospholipid Antibody Syndrome in 123 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sporadic studies suggest hydroxychloroquine (HCQ) may be effective for thrombosis prevention in patients with primary antiphospholipid syndrome (PAPS) and may lead to antiphospholipid antibody (aPL) titer reduction but data from randomized studies are lacking." | 9.34 | The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. ( Koutsogianni, A; Kravvariti, E; Samoli, E; Sfikakis, PP; Tektonidou, MG, 2020) |
| "Objective The objective of this study was to determine the efficacy of hydroxychloroquine (HCQ) in the primary thrombosis prevention of antiphospholipid antibody (aPL)-positive patients with no other systemic autoimmune diseases." | 9.27 | Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. ( Belmont, HM; Branch, DW; Cuadrado, MJ; Erkan, D; Gonzalez, E; Knight, JS; Sciascia, S; Tektonidou, MG; Unlu, O; Uthman, I; Wahl, D; Willis, R; Zhang, Z; Zuily, S, 2018) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 8.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| "In European multicenter study, we aimed to describe the real-life hydroxychloroquine use in APS patients during pregnancy and determine its benefit in refractory obstetrical APS." | 8.91 | The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. ( Alijotas-Reig, J; Andreoli, L; Benbara, A; Bertero, T; Bezanahary, H; Bremme, K; Canti, V; Carbillon, L; Dhote, R; Fain, O; Kuzenko, A; Lazzaroni, MG; Levy, P; Maurier, F; Mekinian, A; Nicaise-Roland, P; Ruffatti, A; Tigazin, A; Tincani, A, 2015) |
| " We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment." | 8.91 | Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? ( Botta, A; De Carolis, MP; De Carolis, S; Del Sordo, G; di Pasquo, E; Garufi, C; Lanzone, A; Salvi, S, 2015) |
| "This study was conducted to analyse the medication indications of hydroxychloroquine (HCQ) and to explore the clinical characteristics and perinatal outcomes of pregnancy in women with autoimmune abnormalities." | 8.31 | The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. ( Liu, Y; Ma, Y; Wang, Y; Ye, S; Zhao, J; Zhao, X, 2023) |
| "Hydroxychloroquine was associated with a higher rate of live births and a lower prevalence of pregnancy complications in refractory primary obstetric APS." | 8.02 | The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. ( Alvarez, R; Balparda, J; Beruti, E; Fernandez Suarez, C; Gerde, M; Heer, C; Ibarra, E; Iglesias, M; Mac Kenzie, R; Rubinstein, F, 2021) |
| "Hydroxychloroquine (HCQ) was suggested to play a role in lowering antiphospholipid antibody titers and preventing thrombotic recurrences in patients with systemic lupus erythematosus, but few data are available in patients with primary antiphospholipid syndrome (PAPS)." | 7.85 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. ( Andreoli, L; Argolini, LM; Calligaro, A; Gerosa, M; Kumar, R; Meroni, PL; Nuri, E; Pengo, V; Ruffatti, A; Taraborelli, M; Tincani, A; Tonello, M, 2017) |
| "Despite the heterogeneity in the 2 groups in terms of systemic lupus erythematosus prevalence and previous pregnancy history, our results support the concept that women with antiphospholipid antibodies may benefit from treatment with hydroxychloroquine during pregnancy to improve pregnancy outcome." | 7.83 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016) |
| "Studies have shown a protective effect of hydroxychloroquine on thrombosis in systemic lupus erythematosus patients." | 7.76 | [Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]. ( Ankri, A; Darnige, L; Fischer, AM; Szymezak, J, 2010) |
| "Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies." | 7.01 | Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. ( Bacal, V; Bedaiwy, MA; Hooper, A, 2023) |
| "Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus." | 6.47 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. ( Petri, M, 2011) |
| "Hydroxychloroquine (HCQ) was originally used as an anti-malaria drug and has now shown benefit in refractory OAPS where conventional treatment has failed, with the expectation of providing protective clinical benefits for both the mother and foetus." | 5.72 | Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome. ( Hu, M; Liu, J; Song, S; Tian, Y; Wan, S; Wang, X; Xia, Y; Zhang, L; Zhang, M; Zhou, Q, 2022) |
| "Thrombosis was assessed both in vitro by measuring thrombin generation time (TGT) and tissue factor (TF) expression and in vivo by the measurement of the time to occlusion in carotid and the total thrombosis area in mesenteric arteries." | 5.51 | Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. ( Benhamou, Y; Billoir, P; Damian, L; Galas, L; Joannides, R; Jouen, F; Le Besnerais, M; Le Cam-Duchez, V; Levesque, H; Miranda, S; Richard, V; Schapman, D; Thiebaut, PA, 2019) |
| "Antiphospholipid syndrome is associated with endothelial dysfunction, which leads to thrombosis and early atheroma." | 5.48 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome. ( Begorre, MA; Belizna, C; Caillon, A; Henrion, D; Kauffenstein, G; Loufrani, L; Poli, C; Urbanski, G, 2018) |
| "Sporadic studies suggest hydroxychloroquine (HCQ) may be effective for thrombosis prevention in patients with primary antiphospholipid syndrome (PAPS) and may lead to antiphospholipid antibody (aPL) titer reduction but data from randomized studies are lacking." | 5.34 | The effect of hydroxychloroquine on thrombosis prevention and antiphospholipid antibody levels in primary antiphospholipid syndrome: A pilot open label randomized prospective study. ( Koutsogianni, A; Kravvariti, E; Samoli, E; Sfikakis, PP; Tektonidou, MG, 2020) |
| "Objective The objective of this study was to determine the efficacy of hydroxychloroquine (HCQ) in the primary thrombosis prevention of antiphospholipid antibody (aPL)-positive patients with no other systemic autoimmune diseases." | 5.27 | Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease. ( Belmont, HM; Branch, DW; Cuadrado, MJ; Erkan, D; Gonzalez, E; Knight, JS; Sciascia, S; Tektonidou, MG; Unlu, O; Uthman, I; Wahl, D; Willis, R; Zhang, Z; Zuily, S, 2018) |
| "Current research in the field of systemic lupus erythematosus (SLE) and pregnancy focuses on predictors of adverse pregnancy outcomes, the safety and efficacy of hydroxychloroquine (HCQ) in pregnancy and the importance of preconception counselling." | 5.05 | [Pregnancy with lupus erythematosus-an update]. ( Fischer-Betz, R; Haase, I, 2020) |
| "The use of low-dose aspirin and heparinoids has improved the pregnancy outcome in obstetric antiphospholipid syndrome (APS)." | 4.93 | The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. ( Branch, DW; Hunt, BJ; Khamashta, M; Levy, RA; Middeldorp, S; Pavord, S; Roccatello, D; Ruiz-Irastorza, G; Schreiber, K; Sciascia, S; Tincani, A, 2016) |
| " Through the dedication and hard work of 50 APS ACTION members, collaborative international projects are currently underway including a multicenter web-based registry and repository of aPL-positive patients, a randomized controlled clinical trial assessing the efficacy of hydroxychloroquine for primary thrombosis prevention in persistently aPL-positive but thrombosis-free patients, standardization of aPL testing through the use of core laboratories worldwide, identification of the limitations in the existing aPL/APS literature, and conducting observational research studies to further our understanding of the disease." | 4.93 | AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update. ( Andrade, D; Barbhaiya, M; Erkan, D, 2016) |
| " We present a case of a woman who had a better pregnancy outcome after the administration of hydroxychloroquine (HCQ) as additional treatment." | 4.91 | Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment? ( Botta, A; De Carolis, MP; De Carolis, S; Del Sordo, G; di Pasquo, E; Garufi, C; Lanzone, A; Salvi, S, 2015) |
| "In European multicenter study, we aimed to describe the real-life hydroxychloroquine use in APS patients during pregnancy and determine its benefit in refractory obstetrical APS." | 4.91 | The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study. ( Alijotas-Reig, J; Andreoli, L; Benbara, A; Bertero, T; Bezanahary, H; Bremme, K; Canti, V; Carbillon, L; Dhote, R; Fain, O; Kuzenko, A; Lazzaroni, MG; Levy, P; Maurier, F; Mekinian, A; Nicaise-Roland, P; Ruffatti, A; Tigazin, A; Tincani, A, 2015) |
| " Current treatment of patients with antiphospholipid syndrome (APS) during pregnancy with heparin and aspirin can act by preventing clot formation and improving live birth rates, but other obstetric morbidities remain high, especially in patients with a history of thrombotic events." | 4.90 | Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment? ( de Jesús, GR; de Jesús, NR; Levy, RA; Rodrigues, G, 2014) |
| "This study was conducted to analyse the medication indications of hydroxychloroquine (HCQ) and to explore the clinical characteristics and perinatal outcomes of pregnancy in women with autoimmune abnormalities." | 4.31 | The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities. ( Liu, Y; Ma, Y; Wang, Y; Ye, S; Zhao, J; Zhao, X, 2023) |
| "A patient in her late 50s with antiphospholipid syndrome presented to general ophthalmology clinic for annual hydroxychloroquine retinopathy screening." | 4.12 | Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate. ( Baxter, SL; Delavar, A, 2022) |
| "Hydroxychloroquine was associated with a higher rate of live births and a lower prevalence of pregnancy complications in refractory primary obstetric APS." | 4.02 | The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome. ( Alvarez, R; Balparda, J; Beruti, E; Fernandez Suarez, C; Gerde, M; Heer, C; Ibarra, E; Iglesias, M; Mac Kenzie, R; Rubinstein, F, 2021) |
| " Several management options for prolongation of pregnancy such as plasma exchange, pravastatin, LMHW, hydroxychloroquine/HCQ, or TNF-alpha blocker should be discussed with the patients." | 3.96 | Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases. ( Cervar-Zivkovic, M; Mayer-Pickel, K; Moertl, M; Schöll, W; Stern, C, 2020) |
| "Hydroxychloroquine (HCQ) was suggested to play a role in lowering antiphospholipid antibody titers and preventing thrombotic recurrences in patients with systemic lupus erythematosus, but few data are available in patients with primary antiphospholipid syndrome (PAPS)." | 3.85 | Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. ( Andreoli, L; Argolini, LM; Calligaro, A; Gerosa, M; Kumar, R; Meroni, PL; Nuri, E; Pengo, V; Ruffatti, A; Taraborelli, M; Tincani, A; Tonello, M, 2017) |
| "Despite the heterogeneity in the 2 groups in terms of systemic lupus erythematosus prevalence and previous pregnancy history, our results support the concept that women with antiphospholipid antibodies may benefit from treatment with hydroxychloroquine during pregnancy to improve pregnancy outcome." | 3.83 | The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. ( Cuadrado, MJ; Hunt, BJ; Khamashta, MA; Lliso, G; Sciascia, S; Talavera-Garcia, E, 2016) |
| " In the univariate analysis, it was associated with age, longer disease duration, antiphospholipid syndrome (APS), higher maximum daily oral prednisolone dose (mg/day), lower mean C3 and C4, higher chronicity index and global sclerosis on renal biopsies (p < 0." | 3.80 | A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis. ( Ghafor, AH; Kong, NC; Said, MS; Shaharir, SS, 2014) |
| "Studies have shown a protective effect of hydroxychloroquine on thrombosis in systemic lupus erythematosus patients." | 3.76 | [Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome]. ( Ankri, A; Darnige, L; Fischer, AM; Szymezak, J, 2010) |
| "Three groups of nine mice were injected with purified immunoglobulin G (IgG) from a patient with the antiphospholipid syndrome (IgG-APS) and then fed with hydroxychloroquine at various doses (100, 6, and 3 mg/kg body wt)." | 3.69 | Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. ( Anderson, G; Barker, JH; Edwards, MH; Harris, EN; Liu, X; Pierangeli, S, 1997) |
| "Hydroxychloroquine (HCQ) is an immunomodulatory agent that has been shown in laboratory studies to decrease thrombosis risk, support placentation, and minimize the destructive effects of antiphospholipid antibodies." | 3.01 | Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review. ( Bacal, V; Bedaiwy, MA; Hooper, A, 2023) |
| "BACKGROUND Lupus anticoagulant-hypoprothrombinemia syndrome (LAHPS) is an exceptionally rare disease caused by prothrombin antibodies, resulting in reduced factor II levels." | 2.82 | Lupus Anticoagulant-Hypoprothrombinemia Syndrome and Pseudotumor Cerebri as an Initial Presentation of Systemic Lupus Erythematosus in a 16-Year-Old Male Patient: A Case Report and Literature Review. ( Alghaythi, AM; Alharbi, AA; AlJohani, G; Omer, MH; Salama, H, 2022) |
| "Management of thrombosis is based on long-term oral anticoagulation and patients with arterial events should be treated aggressively." | 2.53 | Current status and future prospects for the treatment of antiphospholipid syndrome. ( Al Marzooqi, A; Al Saleh, J; Khamashta, M; Leone, A, 2016) |
| "Antiphospholipid syndrome is an autoimmune disease characterized by thrombosis and pregnancy morbidity occurring in patients persistently positive for aPL." | 2.50 | Targeted therapy in antiphospholipid syndrome. ( D'Cruz, DP; Khamashta, MA; Sciascia, S, 2014) |
| "Antiphospholipid syndrome is a rare cause of ocular vaso-occlusive disease, but is associated with significant systemic morbidity and mortality." | 2.48 | Antiphospholipid antibody syndrome. ( Foster, CS; Kruh, JN; Yang, P, 2012) |
| "Hydroxychloroquine also has known benefits in reducing some traditional cardiovascular risk factors, such as hyperlipidemia and diabetes mellitus." | 2.47 | Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. ( Petri, M, 2011) |
| "Hydroxychloroquine has also been shown to reduce in vivo aPL-induced thrombus formation." | 2.42 | Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies. ( Harris, EN; Pierangeli, SS; Vega-Ostertag, M, 2004) |
| "Common complications of systemic lupus erythematosus include nephritis, hematologic complications such as thrombocytopenia, and a variety of neurologic abnormalities." | 1.91 | Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy. ( Craigo, S; Kuller, JA; Norton, ME; Osmundson, SS; Porter, F; Silver, R, 2023) |
| "Catastrophic antiphospholipid antibody syndrome (CAPS) is an accelerated form of disease with rapid involvement of multiple organ systems often posing a diagnostic challenge." | 1.72 | Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean. ( Asturkar, V; Bhanu, K; Dorji, T; Hegde, A; Yangzom, S, 2022) |
| "Hydroxychloroquine (HCQ) was originally used as an anti-malaria drug and has now shown benefit in refractory OAPS where conventional treatment has failed, with the expectation of providing protective clinical benefits for both the mother and foetus." | 1.72 | Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome. ( Hu, M; Liu, J; Song, S; Tian, Y; Wan, S; Wang, X; Xia, Y; Zhang, L; Zhang, M; Zhou, Q, 2022) |
| "After two months, a systemic lupus erythematosus was diagnosed." | 1.62 | Pediatric catastrophic antiphospholipid syndrome patient evolving to systemic lupus erythematosus. ( Carvalho, JF; Shoenfeld, Y; Silva, FF, 2021) |
| "Lupus nephritis was present in 20." | 1.62 | Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal. ( Barros, T; Braga, A; Braga, J; Carvalheira, G; Faria, R; Farinha, F; Marinho, A; Neves, E; Rocha, G; Vasconcelos, C, 2021) |
| "Thrombosis was assessed both in vitro by measuring thrombin generation time (TGT) and tissue factor (TF) expression and in vivo by the measurement of the time to occlusion in carotid and the total thrombosis area in mesenteric arteries." | 1.51 | Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction. ( Benhamou, Y; Billoir, P; Damian, L; Galas, L; Joannides, R; Jouen, F; Le Besnerais, M; Le Cam-Duchez, V; Levesque, H; Miranda, S; Richard, V; Schapman, D; Thiebaut, PA, 2019) |
| "Autoimmune myelofibrosis is a distinct clinicopathological entity that occurs with autoimmune disorders." | 1.51 | Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus. ( Belfeki, N; Declerck, D; Diamantis, S; Shankarasivam, G, 2019) |
| "Antiphospholipid syndrome is associated with endothelial dysfunction, which leads to thrombosis and early atheroma." | 1.48 | Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome. ( Begorre, MA; Belizna, C; Caillon, A; Henrion, D; Kauffenstein, G; Loufrani, L; Poli, C; Urbanski, G, 2018) |
| "Antiphospholipid antibody syndrome is the most common type of acquired thrombophilia disease." | 1.48 | [Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome]. ( Li, XY; Liu, XY; Zhao, JX, 2018) |
| "Hydroxychloroquine was found to be linked to a significantly higher live birth rate with respect to the other oral treatments in the Group II patients." | 1.48 | Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study. ( Alijotas-Reig, J; Andreoli, L; Bertero, MT; Costedoat-Chalumeau, N; Cuadrado, MJ; De Carolis, S; Gerosa, M; Grandone, E; Haladyj, E; Hoxha, A; Khamashta, MA; Latino, JO; Maina, A; Marozio, L; Mayer-Pickel, K; Mekinian, A; Meroni, PL; Morel, N; Pengo, V; Ramoni, V; Reshetnyak, T; Ruffatti, A; Sciascia, S; Serrano, F; Simchen, MJ; Tenti, S; Tincani, A; Tonello, M; Udry, S, 2018) |
| "Twenty-six out of 93 pregnancies with systemic lupus erythematosus (SLE) experienced flares during pregnancy." | 1.42 | Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study. ( Fei, Y; Hao, D; Li, Y; Liu, Y; Luo, Y; Zhang, L; Zhao, Y, 2015) |
| "Papulonodular mucinosis (PNM) in particular is an uncommon cutaneous manifestation of LE." | 1.40 | Papulonodular mucinosis in a patient with systemic lupus erythematosus and antiphospholipid syndrome. ( Desai, S; Korta, DZ; Patel, RR; Sanchez, MR, 2014) |
| "Intrahepatic hemorrhage is a very rare complication of warfarin, and our patient experienced intrahepatic and subgaleal hemorrhage although she did not have any risk factors for bleeding or instability of the international normalized ratio control." | 1.39 | Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy. ( Baek, YH; Cho, DS; Chung, WT; Han, SY; Kang, SH; Lee, SW; Park, IC, 2013) |
| "Hydroxychloroquine (HCQ) has been shown in retrospective studies to decrease aPL titers in laboratory studies, and to decrease thrombosis risk in patients with systemic lupus erythematosus (SLE)." | 1.39 | Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. ( Broder, A; Putterman, C, 2013) |
| "In the end, we hope to find better treatments for antiphospholipid syndrome, which is a leading cause of thrombosis, pregnancy morbidity and other life-altering consequences, and to heighten awareness about this life-threatening, autoimmune condition." | 1.38 | APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking. ( Erkan, D; Lockshin, MD, 2012) |
| "Primary Antiphospholipid Antibody Syndrome (PAPS) and Autoimmune haemolytic anemia (AIHA) is a very rare combination." | 1.35 | Primary antiphospholipid antibody syndrome and autoimmune haemolytic anaemia--a rare combination. ( Baig, MS; Humail, SM; Riaz, A; Suhail, S, 2009) |
| "Association of celiac disease with systemic lupus erythematosus is rare, even though HLA B8 and DR3 are commonly associated with these diseases." | 1.35 | Systemic lupus erythematosus, celiac disease and antiphospholipid antibody syndrome: a rare association. ( Gupta, D; Mirza, N, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (2.44) | 18.2507 |
| 2000's | 13 (10.57) | 29.6817 |
| 2010's | 72 (58.54) | 24.3611 |
| 2020's | 35 (28.46) | 2.80 |
| Authors | Studies |
|---|---|
| Braga, A | 1 |
| Barros, T | 1 |
| Faria, R | 1 |
| Marinho, A | 1 |
| Carvalheira, G | 1 |
| Rocha, G | 1 |
| Farinha, F | 1 |
| Neves, E | 1 |
| Vasconcelos, C | 1 |
| Braga, J | 1 |
| Hussain, H | 1 |
| Tarantino, MD | 1 |
| Chaturvedi, S | 3 |
| McCrae, KR | 4 |
| Roberts, JC | 1 |
| Dorji, T | 1 |
| Hegde, A | 1 |
| Asturkar, V | 1 |
| Yangzom, S | 1 |
| Bhanu, K | 1 |
| Liu, J | 1 |
| Zhang, L | 2 |
| Tian, Y | 2 |
| Wan, S | 1 |
| Hu, M | 1 |
| Song, S | 1 |
| Zhang, M | 1 |
| Zhou, Q | 1 |
| Xia, Y | 2 |
| Wang, X | 2 |
| Silver, R | 1 |
| Craigo, S | 1 |
| Porter, F | 1 |
| Osmundson, SS | 1 |
| Kuller, JA | 1 |
| Norton, ME | 1 |
| Omer, MH | 1 |
| Salama, H | 1 |
| Alghaythi, AM | 1 |
| Alharbi, AA | 1 |
| AlJohani, G | 1 |
| Hubben, A | 1 |
| Delavar, A | 3 |
| Baxter, SL | 3 |
| Ye, S | 2 |
| Zhao, X | 2 |
| Liu, Y | 3 |
| Ma, Y | 2 |
| Wang, Y | 2 |
| Zhao, J | 2 |
| Arachchillage, DJ | 1 |
| Laffan, M | 2 |
| Pericleous, C | 1 |
| Hooper, A | 1 |
| Bacal, V | 1 |
| Bedaiwy, MA | 1 |
| Petri, M | 2 |
| Kravvariti, E | 1 |
| Koutsogianni, A | 1 |
| Samoli, E | 1 |
| Sfikakis, PP | 1 |
| Tektonidou, MG | 4 |
| Mayer-Pickel, K | 2 |
| Stern, C | 1 |
| Cervar-Zivkovic, M | 1 |
| Schöll, W | 1 |
| Moertl, M | 1 |
| Fischer-Betz, R | 1 |
| Haase, I | 1 |
| Doms, J | 1 |
| Horisberger, A | 1 |
| Ribi, C | 1 |
| Hossri, S | 1 |
| Shadi, M | 1 |
| Hamarsha, Z | 1 |
| Schneider, R | 1 |
| El-Sayegh, D | 1 |
| González-García, A | 1 |
| López-Rodríguez, M | 1 |
| Redondo, S | 1 |
| Patier, JL | 1 |
| Masso, P | 1 |
| Tenorio, M | 1 |
| Fajardo, GS | 1 |
| Sarhane, Y | 1 |
| Lacalzada, MM | 1 |
| Manzano, L | 1 |
| Dos Reis Neto, ET | 1 |
| Kakehasi, AM | 1 |
| de Medeiros Pinheiro, M | 1 |
| Ferreira, GA | 1 |
| Marques, CDL | 1 |
| da Mota, LMH | 1 |
| Dos Santos Paiva, E | 1 |
| Pileggi, GCS | 1 |
| Sato, EI | 1 |
| Reis, APMG | 1 |
| Xavier, RM | 1 |
| Provenza, JR | 1 |
| Kong, SS | 1 |
| Azarfar, A | 1 |
| Bhanusali, N | 1 |
| Meng, J | 1 |
| Chen, L | 1 |
| Hou, J | 1 |
| Chi, H | 1 |
| Wang, Z | 1 |
| Yang, C | 2 |
| Su, Y | 1 |
| Frishman, M | 1 |
| Radin, M | 2 |
| Schreiber, K | 5 |
| Yang, CH | 1 |
| Cheng, CY | 1 |
| Chu, KCW | 1 |
| Hsu, CW | 1 |
| Huang, WC | 1 |
| Latino, JO | 3 |
| Udry, S | 3 |
| Aranda, F | 1 |
| Wingeyer, SP | 1 |
| Romero, DSF | 1 |
| Belizna, C | 6 |
| Larrañaga, G | 1 |
| Chiricozzi, A | 1 |
| Garcovich, S | 1 |
| Malvaso, D | 1 |
| Giovanardi, G | 1 |
| Peris, K | 1 |
| Carvalho, JF | 1 |
| Silva, FF | 1 |
| Shoenfeld, Y | 2 |
| Cohen, H | 3 |
| Cuadrado, MJ | 6 |
| Erkan, D | 6 |
| Duarte-Garcia, A | 1 |
| Isenberg, DA | 1 |
| Knight, JS | 3 |
| Ortel, TL | 2 |
| Rahman, A | 2 |
| Salmon, JE | 2 |
| Williams, DJ | 1 |
| Willis, R | 3 |
| Woller, SC | 1 |
| Andrade, D | 4 |
| Devaux, CA | 1 |
| Camoin-Jau, L | 1 |
| Mege, JL | 1 |
| Raoult, D | 1 |
| Gao, R | 1 |
| Qin, L | 1 |
| Xu, J | 1 |
| Chen, D | 1 |
| Peng, B | 1 |
| Khizroeva, J | 2 |
| Bitsadze, V | 2 |
| Tincani, A | 7 |
| Makatsariya, A | 2 |
| Arslanbekova, M | 1 |
| Babaeva, N | 1 |
| Tsibizova, V | 1 |
| Shkoda, A | 1 |
| Makatsariya, N | 1 |
| Tretyakova, M | 1 |
| Solopova, A | 1 |
| Gadaeva, Z | 1 |
| Vorobev, A | 1 |
| Khamani, I | 1 |
| Aslanova, Z | 1 |
| Nakaidze, I | 1 |
| Mischenko, A | 1 |
| Grigoreva, K | 1 |
| Kunesko, N | 1 |
| Egorova, E | 1 |
| Mashkova, T | 1 |
| Saraiva-Mangolin, S | 1 |
| Vaz, CO | 1 |
| Ruiz, T | 1 |
| Mazetto, BM | 1 |
| Orsi, FA | 1 |
| Dong, Y | 1 |
| Lu, Y | 1 |
| Menet, J | 1 |
| Agrinier, N | 1 |
| Dufrost, V | 1 |
| Conart, JB | 1 |
| Wahl, D | 2 |
| Duprez, KA | 1 |
| Zuily, S | 2 |
| Gerde, M | 1 |
| Ibarra, E | 1 |
| Mac Kenzie, R | 1 |
| Fernandez Suarez, C | 1 |
| Heer, C | 1 |
| Alvarez, R | 1 |
| Iglesias, M | 1 |
| Balparda, J | 1 |
| Beruti, E | 1 |
| Rubinstein, F | 1 |
| Arachchillage, DRJ | 1 |
| Gan, SP | 1 |
| Ong, SG | 1 |
| Breen, K | 2 |
| Jacobsen, S | 1 |
| Middeldorp, S | 2 |
| Pavord, S | 2 |
| Regan, L | 1 |
| Roccatello, D | 3 |
| Robinson, SE | 1 |
| Sciascia, S | 7 |
| Seed, PT | 1 |
| Watkins, L | 1 |
| Hunt, BJ | 5 |
| Soh, MC | 1 |
| Nelson-Piercy, C | 1 |
| Westgren, M | 1 |
| McCowan, L | 1 |
| Pasupathy, D | 1 |
| Hsu, YW | 1 |
| Juan, CJ | 1 |
| Lee, JT | 1 |
| Lin, YK | 1 |
| Lai, CH | 1 |
| Yang, FC | 1 |
| Unlu, O | 2 |
| Belmont, HM | 1 |
| Branch, DW | 2 |
| Gonzalez, E | 1 |
| Uthman, I | 3 |
| Zhang, Z | 1 |
| De Carolis, S | 3 |
| Rizzo, F | 1 |
| Tabacco, S | 1 |
| Parmar, K | 1 |
| Rand, JH | 4 |
| Wu, XX | 4 |
| Saurabh, K | 1 |
| Roy, R | 1 |
| Thomas, NR | 1 |
| Chowdhury, M | 1 |
| Omarjee, L | 2 |
| Jaquinandi, V | 1 |
| Camarzana, A | 1 |
| Rouleau, F | 1 |
| Mezdad, TH | 1 |
| Le Tourneau, T | 1 |
| Mahe, G | 2 |
| Ruffatti, A | 6 |
| Tonello, M | 2 |
| Hoxha, A | 1 |
| Reshetnyak, T | 1 |
| Costedoat-Chalumeau, N | 2 |
| Morel, N | 1 |
| Marozio, L | 1 |
| Andreoli, L | 4 |
| Haladyj, E | 1 |
| Meroni, PL | 4 |
| Gerosa, M | 2 |
| Alijotas-Reig, J | 4 |
| Tenti, S | 1 |
| Simchen, MJ | 1 |
| Bertero, MT | 1 |
| Ramoni, V | 1 |
| Mekinian, A | 4 |
| Grandone, E | 1 |
| Maina, A | 1 |
| Serrano, F | 1 |
| Pengo, V | 2 |
| Khamashta, MA | 4 |
| Barailler, H | 1 |
| Milpied, B | 1 |
| Chauvel, A | 1 |
| Claraz, P | 1 |
| Taïeb, A | 1 |
| Seneschal, J | 1 |
| Darrigade, AS | 1 |
| Pregnolato, F | 1 |
| Abad, S | 1 |
| Amital, H | 1 |
| Amoura, Z | 1 |
| Andres, E | 1 |
| Aouba, A | 1 |
| Apras Bilgen, S | 1 |
| Arnaud, L | 1 |
| Bienvenu, B | 1 |
| Blanco, P | 1 |
| Blank, M | 1 |
| Borghi, MO | 1 |
| Caligaro, A | 1 |
| Candrea, E | 1 |
| Canti, V | 2 |
| Chiche, L | 1 |
| Chretien, JM | 1 |
| Cohen Tervaert, JW | 1 |
| Damian, L | 2 |
| Delross, T | 1 |
| Dernis, E | 1 |
| Devreese, K | 1 |
| Djokovic, A | 1 |
| Esteve-Valverde, E | 1 |
| Favaro, M | 1 |
| Fassot, C | 1 |
| Ferrer-Oliveras, R | 1 |
| Godon, A | 1 |
| Hamidou, M | 1 |
| Hasan, M | 1 |
| Henrion, D | 3 |
| Imbert, B | 1 |
| Jeandel, PY | 1 |
| Jeannin, P | 1 |
| Jego, P | 1 |
| Jourde-Chiche, N | 1 |
| Lambotte, O | 1 |
| Landron, C | 1 |
| Lazaro, E | 1 |
| de Leeuw, K | 1 |
| Le Gallou, T | 1 |
| Kiliç, L | 1 |
| Limper, M | 1 |
| Loufrani, L | 3 |
| Lubin, R | 1 |
| Magy-Bertrand, N | 1 |
| Martin, T | 1 |
| Muchardt, C | 1 |
| Nagy, G | 1 |
| Van Paasen, P | 1 |
| Pernod, G | 1 |
| Perrinet, F | 1 |
| Pïres Rosa, G | 1 |
| Pistorius, MA | 1 |
| Said, F | 1 |
| Saulnier, P | 1 |
| Sene, D | 1 |
| Sentilhes, L | 1 |
| Shovman, O | 1 |
| Sibilia, J | 1 |
| Sinescu, C | 1 |
| Stanisavljevic, N | 1 |
| Stojanovich, L | 1 |
| Tam, LS | 1 |
| Tollis, F | 1 |
| Ungeheuer, MN | 1 |
| Versini, M | 1 |
| Cervera, R | 1 |
| Urbanski, G | 1 |
| Caillon, A | 1 |
| Poli, C | 1 |
| Kauffenstein, G | 1 |
| Begorre, MA | 1 |
| Kemp, M | 1 |
| Thomas, W | 1 |
| Placais, L | 1 |
| Carrat, F | 1 |
| Carbillon, L | 3 |
| Nicaise Roland, P | 1 |
| Benbara, A | 2 |
| Cacciatore, C | 1 |
| Fain, O | 3 |
| Li, XY | 1 |
| Zhao, JX | 1 |
| Liu, XY | 1 |
| Emmi, G | 1 |
| Bettiol, A | 1 |
| Palterer, B | 1 |
| Silvestri, E | 1 |
| Vitiello, G | 1 |
| Parronchi, P | 1 |
| Prisco, D | 1 |
| Belfeki, N | 1 |
| Shankarasivam, G | 1 |
| Declerck, D | 1 |
| Diamantis, S | 1 |
| Miranda, S | 1 |
| Billoir, P | 1 |
| Thiebaut, PA | 1 |
| Schapman, D | 1 |
| Le Besnerais, M | 1 |
| Jouen, F | 1 |
| Galas, L | 1 |
| Levesque, H | 2 |
| Le Cam-Duchez, V | 1 |
| Joannides, R | 1 |
| Richard, V | 2 |
| Benhamou, Y | 1 |
| Schmidt-Tanguy, A | 1 |
| Voswinkel, J | 1 |
| Subra, JF | 1 |
| Rohmer, V | 1 |
| Ifrah, N | 1 |
| Broder, A | 2 |
| Putterman, C | 2 |
| Park, IC | 1 |
| Baek, YH | 1 |
| Han, SY | 1 |
| Lee, SW | 2 |
| Chung, WT | 1 |
| Kang, SH | 1 |
| Cho, DS | 1 |
| Albert, CR | 1 |
| Schlesinger, WJ | 1 |
| Viall, CA | 1 |
| Mulla, MJ | 1 |
| Brosens, JJ | 1 |
| Chamley, LW | 1 |
| Abrahams, VM | 1 |
| de Jesús, GR | 1 |
| Rodrigues, G | 1 |
| de Jesús, NR | 1 |
| Levy, RA | 3 |
| Shaharir, SS | 1 |
| Ghafor, AH | 1 |
| Said, MS | 1 |
| Kong, NC | 1 |
| Ibáñez, S | 1 |
| Iruretagoyena, M | 1 |
| Gutiérrez, MA | 1 |
| Aguiar, CL | 1 |
| Danowski, A | 1 |
| Lockshin, MD | 2 |
| Mar, N | 1 |
| Kosowicz, R | 1 |
| Hook, K | 1 |
| D'Cruz, DP | 1 |
| Marchetti, T | 1 |
| Wuillemin, C | 1 |
| de Moerloose, P | 1 |
| Cohen, M | 1 |
| Desai, S | 1 |
| Korta, DZ | 1 |
| Patel, RR | 1 |
| Sanchez, MR | 1 |
| Masseau, A | 1 |
| De Caroli, S | 1 |
| Ambrozic, A | 1 |
| Botta, A | 2 |
| Le Guern, V | 1 |
| Fritsch-Stork, R | 1 |
| Nicaise-Roland, P | 2 |
| Carbonne, B | 1 |
| Yachoui, R | 1 |
| Sehgal, R | 1 |
| Amlani, B | 1 |
| Goldberg, JW | 1 |
| Lazzaroni, MG | 1 |
| Kuzenko, A | 1 |
| Levy, P | 1 |
| Bremme, K | 1 |
| Bezanahary, H | 1 |
| Bertero, T | 1 |
| Dhote, R | 1 |
| Maurier, F | 1 |
| Tigazin, A | 1 |
| Merashli, M | 1 |
| Noureldine, MH | 1 |
| Khamashta, M | 4 |
| Salvi, S | 1 |
| di Pasquo, E | 1 |
| Del Sordo, G | 1 |
| Garufi, C | 1 |
| Lanzone, A | 1 |
| De Carolis, MP | 1 |
| Lopez-Pedrera, Ch | 1 |
| Aguirre, MA | 1 |
| Ruiz-Limon, P | 1 |
| Pérez-Sánchez, C | 1 |
| Jimenez-Gomez, Y | 1 |
| Barbarroja, N | 1 |
| Luo, Y | 1 |
| Fei, Y | 1 |
| Li, Y | 1 |
| Hao, D | 1 |
| Zhao, Y | 1 |
| Ruiz-Irastorza, G | 1 |
| Talavera-Garcia, E | 1 |
| Lliso, G | 1 |
| Elera-Fitzcarrald, C | 1 |
| Alfaro-Lozano, JL | 1 |
| Pastor-Asurza, CA | 1 |
| Tektonidou, M | 1 |
| Al Marzooqi, A | 1 |
| Leone, A | 1 |
| Al Saleh, J | 1 |
| Bertolaccini, ML | 1 |
| Contento, G | 1 |
| Lennen, R | 1 |
| Sanna, G | 1 |
| Blower, PJ | 1 |
| Ma, MT | 1 |
| Sunassee, K | 1 |
| Girardi, G | 1 |
| Nuri, E | 1 |
| Taraborelli, M | 1 |
| Calligaro, A | 1 |
| Argolini, LM | 1 |
| Kumar, R | 1 |
| Barbhaiya, M | 1 |
| van den Hoogen, LL | 1 |
| Fritsch-Stork, RD | 1 |
| Versnel, MA | 1 |
| Derksen, RH | 1 |
| van Roon, JA | 1 |
| Radstake, TR | 1 |
| Yalavarthi, S | 1 |
| Grenn, RC | 1 |
| Wang, TF | 1 |
| Lim, W | 1 |
| Bazzan, M | 1 |
| Quinn, AS | 2 |
| Chen, PP | 2 |
| Hathcock, JJ | 2 |
| Taatjes, DJ | 2 |
| Carragoso, A | 1 |
| Silva, JR | 1 |
| Capelo, J | 1 |
| Faria, B | 1 |
| Gaspar, O | 1 |
| Suhail, S | 1 |
| Baig, MS | 1 |
| Humail, SM | 1 |
| Riaz, A | 1 |
| Ashton, AW | 1 |
| Andree, HA | 1 |
| Mehdi, AA | 1 |
| Szymezak, J | 1 |
| Ankri, A | 1 |
| Fischer, AM | 1 |
| Darnige, L | 1 |
| Zenone, T | 1 |
| Knefati, Y | 1 |
| Katz, SJ | 1 |
| Russell, AS | 1 |
| Scoble, T | 1 |
| Wijetilleka, S | 1 |
| Guller, S | 1 |
| Noaiseh, G | 1 |
| Bhangle, S | 1 |
| Vivino, F | 1 |
| Hong, JY | 1 |
| Lai, CC | 1 |
| Chang, YS | 1 |
| Hsiao, KH | 1 |
| Chou, CT | 1 |
| Chen, WS | 1 |
| Yang, P | 1 |
| Kruh, JN | 1 |
| Foster, CS | 1 |
| Lim, LS | 1 |
| Feldman, BM | 1 |
| Yoon, KH | 1 |
| Nasonov, EL | 1 |
| Pierangeli, SS | 1 |
| Vega-Ostertag, M | 1 |
| Harris, EN | 2 |
| Chen, HC | 1 |
| Lai, JH | 1 |
| Huang, GS | 1 |
| Gao, HW | 1 |
| Chen, CH | 1 |
| Kuo, SY | 1 |
| Chang, DM | 1 |
| Lai, TY | 1 |
| Ngai, JW | 1 |
| Chan, WM | 1 |
| Lam, DS | 1 |
| Zajdenweber, ME | 1 |
| Muccioli, C | 1 |
| Moraes, RT | 1 |
| Logan, P | 1 |
| Fernandes, BF | 1 |
| Burnier, MN | 1 |
| Belizna, CC | 1 |
| Thuillez, C | 1 |
| Gupta, D | 1 |
| Mirza, N | 1 |
| Van Horn, G | 1 |
| Arnett, FC | 1 |
| Dimachkie, MM | 1 |
| Wallace, DJ | 1 |
| Edwards, MH | 1 |
| Pierangeli, S | 1 |
| Liu, X | 1 |
| Barker, JH | 1 |
| Anderson, G | 1 |
| Maddison, PJ | 1 |
| Thorpe, C | 1 |
| Seale, JR | 1 |
| Ahmed, W | 1 |
| Whiteley, GS | 1 |
| Granel, B | 1 |
| Serratrice, J | 1 |
| Swiader, L | 1 |
| Gambarelli, F | 1 |
| Daniel, L | 1 |
| Fossat, C | 1 |
| Hesse-Bonérandi, S | 1 |
| Pache, X | 1 |
| Disdier, P | 1 |
| Weiller, PJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| "Constitution d'Une Cohorte Prospective de Sujets Sains et Malades et d'Une Collection de Ressources Biologiques associées Pour l'étude du système Immunitaire et de Ses déterminants Génétiques et Environnementaux"[NCT03925272] | 2,200 participants (Anticipated) | Interventional | 2011-02-02 | Recruiting | |||
| Collection d'échantillons Biologiques Humains de Sujets Sains et Malades Pour la Mise au Point et la Validation de Nouvelles méthodes de Diagnostic et Pour la réalisation d'Expertises Dans le Domaine Des Maladies Infectieuses et Tropicales[NCT03912246] | 800 participants (Actual) | Interventional | 2009-04-27 | Completed | |||
| A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome[NCT04624269] | Phase 4 | 384 participants (Anticipated) | Interventional | 2020-12-01 | Not yet recruiting | ||
| Evaluation of the Benefit of Adjuvant Treatment With Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome[NCT04275778] | Phase 2 | 110 participants (Anticipated) | Interventional | 2021-07-09 | Recruiting | ||
| A Three-arm, Multicenter, Open-label Randomized Controlled Trial of Hydroxychloroquine and Low-dose Prednisone on Recurrent Spontaneous Abortion With Undifferentiated Connective Tissue Diseases: Protocol for the Immunosuppressant Regimens for Living FEtus[NCT03671174] | 420 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients.[NCT01784523] | Phase 3 | 11 participants (Actual) | Interventional | 2013-02-28 | Terminated (stopped due to low recruitment rate exacerbated by manufacturing shortage and price increase of hydroxychloroquine.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the efficacy of Hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis free patients with no other systemic autoimmune diseases over the five year study period. (NCT01784523)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard Treatment | 0 |
| Hydroxychloroquine | 0 |
49 reviews available for hydroxychloroquine and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Lupus Anticoagulant-Hypoprothrombinemia Syndrome and Pseudotumor Cerebri as an Initial Presentation of Systemic Lupus Erythematosus in a 16-Year-Old Male Patient: A Case Report and Literature Review.
Topics: Adolescent; Adrenal Cortex Hormones; Antiphospholipid Syndrome; Hemorrhage; Humans; Hydroxychloroqui | 2022 |
Emerging Therapies in Antiphospholipid Syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Hydroxychlo | 2022 |
Hydroxychloroquine as an Immunomodulatory and Antithrombotic Treatment in Antiphospholipid Syndrome.
Topics: Anticoagulants; Antimalarials; Antiphospholipid Syndrome; Female; Fibrinolytic Agents; Humans; Hydro | 2023 |
Does adding hydroxychloroquine to empiric treatment improve the live birth rate in refractory obstetrical antiphospholipid syndrome? A systematic review.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Birth Rate; | 2023 |
Pregnancy and Systemic Lupus Erythematosus.
Topics: Adult; Antimalarials; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newborn | 2020 |
[Pregnancy with lupus erythematosus-an update].
Topics: Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregna | 2020 |
[Management of the antiphospholipid syndrome in adults].
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Female; Humans; Hydr | 2020 |
Aortitis in the setting of catastrophic antiphospholipid syndrome in a patient with systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Ao | 2020 |
Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases.
Topics: Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Chloroquine; | 2020 |
Sneddon syndrome: under diagnosed disease, complex clinical manifestations and challenging diagnosis. A case-based review.
Topics: Adult; Antiphospholipid Syndrome; Antirheumatic Agents; Factor Xa Inhibitors; Female; Humans; Hydrox | 2021 |
Probable catastrophic antiphospholipid syndrome secondary to chronic myelomonocytic leukaemia in an adult patient and a mini review.
Topics: Antiphospholipid Syndrome; Bone Marrow; Computed Tomography Angiography; Humans; Hydroxychloroquine; | 2020 |
Hydroxychloroquine and antiphospholipid antibody-related pregnancy morbidity: a systematic review and meta-analysis.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Case-Control Studies; Female; Humans; Hydro | 2020 |
16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Congresses as Topic; Factor | 2020 |
Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; COVID-19; COVID-19 Drug Treatment; Humans; | 2021 |
The additional use of hydroxychloroquine can improve the live birth rate in pregnant women with persistent positive antiphospholipid antibodies: A systematic review and meta-analysis.
Topics: Adult; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy Complicat | 2021 |
Pathogenesis and management of antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; beta 2-Glycoprotein I; Complement Inactiv | 2017 |
Do adverse pregnancy outcomes contribute to accelerated cardiovascular events seen in young women with systemic lupus erythematosus?
Topics: Adult; Antiphospholipid Syndrome; Cardiovascular Diseases; Female; Humans; Hydroxychloroquine; Lupus | 2017 |
Diagnosis and management of the antiphospholipid syndrome.
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; Disease Management; En | 2017 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Delivery, Obstetric; Female; Humans; Hydroxychloroquine; Pregnancy; Pregn | 2018 |
Antiphospholipid syndrome in obstetrics.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; | 2018 |
Pregnancy morbidity in antiphospholipid syndrome: what is the impact of treatment?
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fetal Growth Retarda | 2014 |
[New alternatives for the treatment of antiphospholipid syndrome. A literature review].
Topics: Agmatine; Antibodies, Monoclonal, Murine-Derived; Antiphospholipid Syndrome; Dipeptides; Glucocortic | 2013 |
14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Factor Xa; Humans; Hydroxyc | 2014 |
Targeted therapy in antiphospholipid syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antigens, CD20; Antiphospholipid Syndrome; Humans; Hyd | 2014 |
Obstetrical APS: is there a place for hydroxychloroquine to improve the pregnancy outcome?
Topics: Anti-Inflammatory Agents; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnancy; | 2015 |
Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Blood Platelets; Erythrocytes; Hum | 2015 |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Multice | 2015 |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Multice | 2015 |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Multice | 2015 |
The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: Data from a European multicenter retrospective study.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Multice | 2015 |
Antiphospholipid syndrome: an update.
Topics: Adrenal Cortex Hormones; Animals; Annexin A2; Anticoagulants; Antiphospholipid Syndrome; Drugs, Inve | 2015 |
Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; | 2015 |
Immunotherapy in antiphospholipid syndrome.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Biological Products; Humans; Hydroxychloroquine; | 2015 |
The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Cohort Studies; Female; Heparin; H | 2016 |
The antiphospholipid syndrome: still an enigma.
Topics: Administration, Oral; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; beta | 2015 |
Emerging Therapies in Antiphospholipid Syndrome.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Complement Inactivating Agents; Disease Models, | 2016 |
Current status and future prospects for the treatment of antiphospholipid syndrome.
Topics: Animals; Anticoagulants; Antiphospholipid Syndrome; Autoantibodies; Female; Humans; Hydroxychloroqui | 2016 |
Prevention & treatment of obstetrical complications in APS: Is hydroxychloroquine the Holy Grail we are looking for?
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnan | 2016 |
AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION): 5-Year Update.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Clinical Trials as To | 2016 |
Pregnancy and Antiphospholipid Syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Fetal Growth Retardation; Humans; H | 2016 |
What is the role of hydroxychloroquine in reducing thrombotic risk in patients with antiphospholipid antibodies?
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Humans; Hydroxychloroquine; Male; Ve | 2016 |
Novel diagnostic and therapeutic frontiers in thrombotic anti-phospholipid syndrome.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antic | 2017 |
Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease.
Topics: Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Antirheumatic Agents; Catastrophic Ill | 2017 |
Antiphospholipid syndrome: pathogenesis and a window of treatment opportunities in the future.
Topics: Annexin A2; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Antibodies, Monoclonal; Antibodi | 2010 |
Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Enzyme Inhibitors; Humans; Hydroxychloroqui | 2011 |
Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action.
Topics: Annexin A5; Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Cardiovascular Diseases; | 2011 |
Management of refractory anti-phospholipid syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antiphospholipid Syndrome; Clinical Trials as Topic; Evidenc | 2011 |
Antiphospholipid antibody syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; beta 2-Glycoprotein I; Humans; Hyd | 2012 |
Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies.
Topics: Animals; Antibodies, Antiphospholipid; Antibodies, Monoclonal; Antiphospholipid Syndrome; Endotheliu | 2004 |
Systemic lupus erythematosus with simultaneous onset of Kikuchi-Fujimoto's disease complicated with antiphospholipid antibody syndrome: a case report and review of the literature.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; An | 2005 |
Insights into atherosclerosis therapy in antiphospholipid syndrome.
Topics: Adrenal Cortex Hormones; Animals; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Antiphosph | 2007 |
The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: a critical review.
Topics: Antimalarials; Antiphospholipid Syndrome; Autoimmune Diseases; Chloroquine; Controlled Clinical Tria | 1996 |
3 trials available for hydroxychloroquine and Anti-Phospholipid Antibody Syndrome
71 other studies available for hydroxychloroquine and Anti-Phospholipid Antibody Syndrome
| Article | Year |
|---|---|
Systemic lupus erythematosus and pregnancy: A retrospective single-center study of 215 pregnancies from Portugal.
Topics: Abortion, Spontaneous; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Infant, Newbor | 2021 |
Eculizumab for refractory thrombosis in antiphospholipid syndrome.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Aspirin; Clopidogrel; Fema | 2022 |
Catastrophic Anti-Phospholipid Syndrome in Systemic Lupus Erythematosus: A Tsunami in the Ocean.
Topics: Adult; Antiphospholipid Syndrome; Cyclophosphamide; Female; Humans; Hydroxychloroquine; Immunoglobul | 2022 |
Protection by hydroxychloroquine prevents placental injury in obstetric antiphospholipid syndrome.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine | 2022 |
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Wei | 2023 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
Cilioretinal artery occlusion in antiphospholipid syndrome and the decision to anticoagulate.
Topics: Anticoagulants; Antiphospholipid Syndrome; Arteries; Blindness; Cerebrovascular Disorders; Female; H | 2022 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
The use of hydroxychloroquine in pregnancy and its effect on perinatal outcomes in a population with autoimmune abnormalities.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Autoantibodies; Female; Humans; Hydroxychloroquine; | 2023 |
Preeclampsia before fetal viability in women with primary antiphospholipid syndrome- materno-fetal outcomes in a series of 7 cases.
Topics: Adult; Antiphospholipid Syndrome; Female; Fetal Viability; Gestational Age; Heparin, Low-Molecular-W | 2020 |
Clinically significant anticardiolipin antibodies associated with COVID-19.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiphospholi | 2020 |
Man With Right Flank Pain.
Topics: Anticoagulants; Antiphospholipid Syndrome; Antirheumatic Agents; Flank Pain; Humans; Hydroxychloroqu | 2020 |
Risk factors for early severe preeclampsia in obstetric antiphospholipid syndrome with conventional treatment. The impact of hydroxychloroquine.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Heparin; Humans; Hy | 2020 |
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus.
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Antirheu | 2020 |
Pediatric catastrophic antiphospholipid syndrome patient evolving to systemic lupus erythematosus.
Topics: Adolescent; Antibodies, Antinuclear; Antiphospholipid Syndrome; Catastrophic Illness; Female; Hepari | 2021 |
Correspondence on 'EULAR recommendations for the management of antiphospholipid syndrome in adults'.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Humans; Hydroxychloroquine | 2023 |
Hydroxychloroquine in obstetric antiphospholipid syndrome: rationale and results of an observational study of refractory cases.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Endothelial Cells; | 2022 |
Use of hydroxychloroquine to control immune response and hypercoagulability in patients with primary antiphospholipid syndrome.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Humans; Hydroxychloroquine; Immunity; Throm | 2021 |
Effect of hydroxychloroquine on antiphospholipid antibodies-inhibited endometrial angiogenesis.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Endothelial Cells; Fema | 2022 |
Ophthalmologic manifestations in patients with antiphospholipid antibodies: Beware of iatrogenic complications.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Eye Disease | 2021 |
The impact of hydroxychloroquine on obstetric outcomes in refractory obstetric antiphospholipid syndrome.
Topics: Antiphospholipid Syndrome; Cohort Studies; Female; Humans; Hydroxychloroquine; Placenta; Pregnancy; | 2021 |
Antithrombotic effects of hydroxychloroquine in a pregnant patient with Antiphospholipid syndrome and recurrent venous thromboembolism.
Topics: Antiphospholipid Syndrome; Antithrombins; Female; Humans; Hydroxychloroquine; Pregnancy; Pregnancy C | 2017 |
Anti-N-Methyl-D-Aspartate-Receptor Encephalitis Complicated With Antiphospholipid Syndrome and Cerebral Venous Thrombosis.
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Antiphospholipid Syndrome; Antirheumatic Agents; Br | 2017 |
Hydroxychloroquine as additional treatment in pregnant patients with refractory APS.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Female; Humans; Hydroxychloroquine; Pregnan | 2017 |
The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies.
Topics: Adolescent; Adult; Aged; Annexin A5; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphos | 2018 |
Multimodal imaging characteristics of hydroxychloroquine retinopathy.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Diagnosis, Differential; Female; Fluorescein Angiog | 2018 |
Improvement of Libman-Sacks Endocarditis With Combined Hydroxychloroquine-Vitamin K Antagonist Therapy in a Primary Antiphospholipid Syndrome Patient.
Topics: Anticoagulants; Antiphospholipid Syndrome; Antirheumatic Agents; Drug Therapy, Combination; Endocard | 2018 |
Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study.
Topics: Administration, Oral; Adult; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Antiphosphol | 2018 |
Delayed hypersensitivity skin reaction to hydroxychloroquine: Successful short desensitization.
Topics: Aged, 80 and over; Antiphospholipid Syndrome; Clinical Protocols; Desensitization, Immunologic; Drug | 2019 |
Hydroxychloroquine partially prevents endothelial dysfunction induced by anti-beta-2-GPI antibodies in an in vivo mouse model of antiphospholipid syndrome.
Topics: Animals; Antibodies, Anti-Idiotypic; Antiphospholipid Syndrome; beta 2-Glycoprotein I; Disease Model | 2018 |
Obstetrical morbidity related to anti-SSA antibodies: Data from a French monocentric retrospective study.
Topics: Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Aspirin; Databases, Factual; Female; Fran | 2019 |
[Diagnosis and treatment of antiphospholipid antibody-related recurrent spontaneous abortion and analysis of therapeutic drugs and pregnancy outcome in 75 patients with antiphospholipid syndrome].
Topics: Abortion, Habitual; Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2018 |
Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment.
Topics: Antibodies, Antiphospholipid; Antibodies, Monoclonal, Humanized; Antiphospholipid Syndrome; Glycopro | 2019 |
Autoimmune myelofibrosis: a rare haematological involvement in systemic lupus erythematosus.
Topics: Adult; Anti-Inflammatory Agents; Antiphospholipid Syndrome; Antirheumatic Agents; Autoimmune Disease | 2019 |
Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Disease Models, Animal; Endothelia | 2019 |
Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients.
Topics: Adult; Antiphospholipid Syndrome; Humans; Hydroxychloroquine; Thrombosis | 2013 |
Commentary on "The risky business of studying prognosis".
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Female; Humans; Hydro | 2013 |
Simultaneous intrahepatic and subgaleal hemorrhage in antiphospholipid syndrome following anticoagulation therapy.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Chemical and Drug Induced Liver Injury; Clopi | 2013 |
Drs. Lim and Feldman reply.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Female; Humans; Hydro | 2013 |
Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Cell Line; Cell Movem | 2014 |
A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis.
Topics: Adult; Antiphospholipid Syndrome; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Human | 2014 |
Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.
Topics: Abortion, Spontaneous; Adult; Antiphospholipid Syndrome; Enzyme Inhibitors; Female; Humans; Hydroxyc | 2014 |
Hydroxychloroquine restores trophoblast fusion affected by antiphospholipid antibodies.
Topics: Adult; Antibodies; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; beta 2-Glycoprotein I; C | 2014 |
Papulonodular mucinosis in a patient with systemic lupus erythematosus and antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Immunosuppr | 2014 |
Antiphospholipid antibodies-associated diffuse alveolar hemorrhage.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Azath | 2015 |
Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years--a retrospective cohort study.
Topics: Abortion, Spontaneous; Adult; Antibodies, Antinuclear; Antiphospholipid Syndrome; Connective Tissue | 2015 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; | 2016 |
Garre's sclerosing osteomyelitis caused by salmonella group D in a patient with systemic lupus erythematosus: an unusual complication.
Topics: Adult; Anti-Bacterial Agents; Antiphospholipid Syndrome; Ceftazidime; Doxycycline; Femur; Humans; Hy | 2015 |
Complement inhibition by hydroxychloroquine prevents placental and fetal brain abnormalities in antiphospholipid syndrome.
Topics: Adult; Animals; Antimalarials; Antiphospholipid Syndrome; Brain; Complement Activation; Complement C | 2016 |
Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome.
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Antiphosp | 2017 |
Monocyte type I interferon signature in antiphospholipid syndrome is related to proinflammatory monocyte subsets, hydroxychloroquine and statin use.
Topics: Antiphospholipid Syndrome; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitor | 2016 |
Response to: 'Monocyte type I interferon signature in antiphospholipid syndrome is related to pro-inflammatory monocyte subsets, hydroxychloroquine and statin use' by van den Hoogen et al.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Humans; Hydroxychloroquine; Hydroxymethylgl | 2016 |
Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antigen-Antibody Complex; Antimalarials; Antiphospholi | 2008 |
A patient with sarcoidosis and antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Antirheumatic Agents; Drug Therapy, Combination; Female; | 2008 |
Primary antiphospholipid antibody syndrome and autoimmune haemolytic anaemia--a rare combination.
Topics: Adolescent; Adrenal Cortex Hormones; Anemia, Hemolytic, Autoimmune; Anticoagulants; Antiphospholipid | 2009 |
Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.
Topics: Annexin A5; Antibodies, Antiphospholipid; Anticoagulants; Antimalarials; Antiphospholipid Syndrome; | 2010 |
[Hydroxychloroquine: a new therapeutic approach to the thrombotic manifestations of antiphospholipid syndrome].
Topics: Annexin A5; Antiphospholipid Syndrome; Antirheumatic Agents; Biomarkers; Enzyme Inhibitors; Evidence | 2010 |
[Renal infarction in systemic lupus with antiphospholipid syndrome: role of hydroxychloroquine withdrawal? Comment on the article by Szymezak et al].
Topics: Adult; Antibodies, Anticardiolipin; Antibodies, Antinuclear; Anticoagulants; Antiphospholipid Syndro | 2011 |
Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression.
Topics: Annexin A5; Antibodies, Antiphospholipid; Antibodies, Monoclonal; Antigen-Antibody Complex; Antimala | 2011 |
Idiopathic mediastinal fibrosis presenting with antiphospholipid antibody syndrome and manifestations suggestive of connective tissue disease.
Topics: Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Antirheumatic Agents; Azathioprine; Connecti | 2012 |
APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking.
Topics: Antiphospholipid Syndrome; Antirheumatic Agents; Humans; Hydroxychloroquine; Randomized Controlled T | 2012 |
Intestinal vasculitis and renal infarction in a lupus patient with antiphospholipid syndrome.
Topics: Adolescent; Antiphospholipid Syndrome; Comorbidity; Drug Therapy, Combination; Female; Humans; Hydro | 2012 |
Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus.
Topics: Adult; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Female; Humans | 2013 |
The risky business of studying prognosis.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Antirheumatic Agents; Female; Humans; Hydro | 2013 |
Sufficient evidence to consider hydroxychloroquine as an adjunct therapy in antiphospholipid antibody (Hughes') syndome.
Topics: Antiphospholipid Syndrome; Chemotherapy, Adjuvant; Clinical Trials as Topic; Dose-Response Relations | 2002 |
[Current approaches to prevention and treatment of antiphospholipid syndrome].
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Contraceptives, Oral; Enzyme Inhibitors; | 2003 |
Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy.
Topics: Adult; Aged; Antiphospholipid Syndrome; Antirheumatic Agents; Arthritis, Rheumatoid; Cross-Sectional | 2006 |
Localized retinal ischemia as an ocular manifestation of primary antiphospholipid syndrome.
Topics: Adult; Antiphospholipid Syndrome; Fluorescein Angiography; Humans; Hydroxychloroquine; Ischemia; Mal | 2007 |
Systemic lupus erythematosus, celiac disease and antiphospholipid antibody syndrome: a rare association.
Topics: Adult; Antiphospholipid Syndrome; Antirheumatic Agents; Celiac Disease; Diet, Gluten-Free; Female; H | 2008 |
Reversible dementia and chorea in a young woman with the lupus anticoagulant.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Autoimmune Diseases; Chorea; Dementia; Depression; Diagno | 1996 |
Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Dose-Response Relationship, Drug; | 1997 |
'Catastrophic' antiphospholipid syndrome.
Topics: Anti-Inflammatory Agents; Anticoagulants; Antiphospholipid Syndrome; Antirheumatic Agents; Critical | 2000 |
Crossing of antinuclear antibodies and anti-leishmania antibodies.
Topics: Adult; Antibodies, Antinuclear; Antibodies, Protozoan; Antiphospholipid Syndrome; Antirheumatic Agen | 2000 |